NATIONAL CANCER CONTROL PROGRAMME
NOP online
ISSN 1802-887X
CANCON
 
data and background information Registries monitoring the use of targeted therapies

Registries monitoring the use of targeted therapies

Clinical registries present an important tool recording the administration of biological therapies in the Czech Republic and its results. The Czech Society for Oncology maintains clinical registries of cancer patients treated with biological therapies in Comprehensive Cancer Centres. These registries make it possible to evaluate the benefits and safety of treatment. Although recording data on biological therapies is not obligatory, data on more than 90 % of patients treated with these preparations are recorded. Data is recorded in a de-identified form, i.e. a specific patient cannot be identified. Registries on the administration of biological therapies are maintained by the Czech Society of Oncology in cooperation with the Institute of Biostatistics and Analyses Ltd, and the Masaryk Memorial Cancer Institute. More information is available in the description of the below-mentioned projects.

Breast

Breast

Terminated clinical registry of breast cancer patients who were treated with trastuzumab (Herceptin®), lapatinib (Tyverb®), bevacizumab (Avastin®) and/or everolimus (Afinitor®).

Corect

Corect

Terminated clinical registry of colorectal cancer (CRC) patients who were treated with cetuximab (Erbitux®), bevacizumab (Avastin®) and/or panitumumab (Vectibix®).

Melanom

Melanom

Clinical registry of melanoma patients who have been treated with dabrafenib (Tafinlar®), ipilimumab (Yervoy®), nivolumab (Opdivo®), trametinib (Mekinist®), pembrolizumab (Keytruda®) and/or vemurafenib (Zelboraf®).

OVARIA

OVARIA

Terminated clinical registry of ovarian cancer patients who were treated with bevacizumab (Avastin®) and/or olaparib (Lynparza®).

Pemetrexed

Pemetrexed

Clinical registry of pleural mesothelioma patients who have been treated with pemetrexed (Alimta®).

RenIS

RenIS

Terminated clinical registry of kidney cancer patients who were treated with bevacizumab (Avastin®), everolimus (Afinitor®), pazopanib (Votrient®), sorafenib (Nexavar®), sunitinib (Sutent®) and/or temsirolimus (Torisel®).

Tulung

Tulung

Clinical registry of non-small cell lung cancer (NSCLC) patients who have been treated with bevacizumab (Avastin®), erlotinib (Tarceva®), gefitinib (Iressa®), pemetrexed (Alimta®), afatinib (Giotrif®) and/or nintedanib (Vargatef®).